Shots:
- Merck has signed a definitive agreement to acquire Cidara Therapeutics through a subsidiary, adding the company’s lead late-stage antiviral candidate CD388 to its pipeline
- Merck will acquire Cidara at $221.50 per share in cash, valuing the deal at approximately $9.2B. The transaction is expected to close in Q1’26
- Cidara’s CD388 (currently in P-III) is a small-molecule neuraminidase inhibitor stably conjugated to a proprietary human antibody Fc fragment, designed to provide long-acting protection against both influenza A and B
Ref: Cidara Therapeutics | Image: Cidara Therapeutics | Press Release
Related News:- Merck Reveals P-III (CORALreef HeFH) Trial Data on Enlicitide Decanoate for Heterozygous Familial Hypercholesterolemia (HeFH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
